- VERIFIED ANALYTICAL DATA AVAILABLE
- SECURE INSTITUTIONAL PORTAL
- In-Vitro Laboratory Research Use Only
Cagrilintide is a long-acting, acylated synthetic analog of human amylin (islet amyloid polypeptide, IAPP). It is designed to address the rapid degradation and aggregation limitations of native amylin and is utilized in experimental systems to study amylin receptor signaling, neuroendocrine regulation, and metabolic pathway modulation. Structural modification with a C-20 fatty diacid side chain promotes albumin binding, enabling extended exposure profiles in pharmacokinetic and systems biology research models.
Cagrilintide is used to investigate the biology of the amylin receptor complex, which consists of the Calcitonin Receptor (CTR) in association with Receptor Activity-Modifying Proteins (RAMPs).
Receptor Agonism
Research examines binding affinity and activation kinetics at AMY1, AMY2, and AMY3 receptor subtypes using receptor-transfected cell models.
Intracellular Cascades
Downstream signaling pathways are evaluated via cAMP accumulation assays and ERK1/2 phosphorylation measurements.
Desensitization Profiles
Comparative studies assess receptor internalization and signaling persistence relative to native amylin under controlled experimental exposure.
Research focuses on amylin-mediated signaling within central nervous system regions involved in energy balance regulation.
Satiety Signaling
Experimental models map neuronal activation patterns (e.g., c-Fos expression) within the area postrema and nucleus of the solitary tract.
Gastric Motility
Studies assess alterations in gastric emptying dynamics and vagal nerve signaling in preclinical systems.
Glucagon Modulation
Investigations explore paracrine signaling effects on pancreatic alpha-cells using isolated islet and ex-vivo models.
Structural modifications in Cagrilintide enable examination of amylin analog stability and systemic exposure characteristics.
Proteolytic Resistance
Assays measure degradation rates in plasma and protease-rich environments.
Albumin Binding
Non-covalent albumin interaction mediated by the C-20 fatty diacid chain is characterized to support pharmacokinetic modeling.
Aggregation Assays
Studies evaluate reduced amyloid fibril formation relative to human amylin (hIAPP) under controlled laboratory conditions.
Cagrilintide is frequently incorporated into combination signaling studies examining integrated metabolic regulation.
GLP-1 Interaction Models
Co-treatment studies with GLP-1 receptor agonists investigate additive or synergistic receptor-level signaling effects.
Glucose Homeostasis Models
Cellular and ex-vivo systems assess glucose uptake and metabolic signaling under dual-pathway activation.
Species Specificity
Amylin receptor distribution and pharmacology vary between rodent models and human physiology, limiting direct translational interpretation.
Solubility Considerations
Despite chemical modifications, amylin analogs may present solubility challenges at neutral pH during complex assay preparation.
In Vitro vs. In Vivo
All observations referenced derive from cellular or animal model experiments. No clinical safety, efficacy, or human use is implied.
Hay, D. L., et al. (2015).
Amylin: Pharmacology, physiology and clinical potential.
Pharmacological Reviews.
Roth, J. D., et al. (2012).
Leptin responsiveness restored by amylin.
Proceedings of the National Academy of Sciences (PNAS).
Hay, D. L., et al. (2018).
Amylin receptors: molecular composition and pharmacology.
Biochemical Society Transactions.
Drucker, D. J., et al. (2020).
Mechanisms of action and therapeutic application of glucagon-like peptide-1.
Cell Metabolism.
(Cited for combination signaling context.)
